We are live on ! Find out more
TARA icon

Protara Therapeutics

31 hedge funds and large institutions have $14.7M invested in Protara Therapeutics in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $4K | Put options by funds: $2K

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

0% more funds holding

Funds holding: 31 → 31 (0)

1.64% less ownership

Funds ownership: 50.25% → 48.61% (-1.6%)

33% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 9

82% less capital inflows, than outflows

Capital inflows: $281K | Capital outflows: $1.52M

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
31
Holders Change
–
Holders Change %
0%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
3
Increased
6
Reduced
9
Closed
2
Calls
$4​K
Puts
$2​K
Net Calls
+$2​K
Net Calls Change
–

TARA Hedge Fund Activity: Q4 2022 in Review

31 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q4 2022, worth a combined $14.7M — down 16% from $17.4M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new TARA positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 9 trimmed.

The largest buyer was Privium Fund Management (UK), adding an estimated $267K. The largest seller was Financial Advocates Investment Management, exiting entirely with an estimated $678K sold.

  • 31 institutional investors held Protara Therapeutics (TARA) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $14.7M of Protara Therapeutics stock for Q4 2022, down 16% quarter-over-quarter.
  • 3 funds opened new Protara Therapeutics positions in Q4 2022 and 2 closed out, a net change of +1 holder.
  • The largest Protara Therapeutics buyer in Q4 2022 was Privium Fund Management (UK), an estimated $267K added.
  • The largest Protara Therapeutics seller in Q4 2022 was Financial Advocates Investment Management, an estimated $678K sold.

Based on aggregated 13F filings for Q4 2022.